Pepper Bio landed $6.5 million in seed funding led by NFX. The startup wants to improve the drug-discovery process for pharma companies using AI.
Business Insider’s Post
More Relevant Posts
-
California based biotech startup Inceptive has raised a $100 million from Andreessen Horowitz (a VC fund) and NVIDIA (a software giant in #artificialintelligence) for exploring #GenAI applications in drug development Inceptive is founded by Jakob Uszkoreit, who is a former Google artificial intelligence expert and has co-authored a paper that kick-started #generativeAI advances such as #ChatGPT According to a report by Morgan Stanley, there is a $50 billion market opportunity for Generative AI in #pharmaceuticals The startup was founded in 2021 and was valued at $100 million. The latest round of funding propels the company's valuation to more than $300 million. Some of the key highlights of the company include: 1. It has built an AI platform that designs mRNA molecules using large-scale deep learning in a tight loop with high-throughput experiments 2. Once the molecules have been identified, Inceptive tests these in labs and licenses the molecules out to pharmaceutical companies to assemble and put through clinical trials 3. It is also working with a a large European pharmaceutical company, which is experimenting with the start-up’s molecules to develop a new infectious disease vaccine Source: Financial Times Liked the article? Follow for more interesting weekly pharma updates Svantis is a business consulting firm focused on providing market intelligence, business insights and competitive intelligence in the pharmaceutical industry #svantis #pharma #genai #marketresearch
To view or add a comment, sign in
-
𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲: 𝗔𝗹𝗽𝗵𝗮𝗯𝗲𝘁'𝘀 𝗜𝘀𝗼𝗺𝗼𝗿𝗽𝗵𝗶𝗰 𝗶𝗻𝗸𝘀 𝗳𝗶𝗿𝘀𝘁 𝗽𝗵𝗮𝗿𝗺𝗮 𝗱𝗲𝗮𝗹𝘀 𝘄𝗶𝘁𝗵 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗮𝗻𝗱 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗳𝗼𝗿 $𝟴𝟯𝗠 𝘂𝗽𝗳𝗿𝗼𝗻𝘁, $𝟮.𝟵𝗕 𝗶𝗻 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 Isomorphic Labs, Alphabet Inc.’s closely watched AI startup, has signed its first pharma partnerships, and will work with Eli Lilly and Novartis in deals that could be worth $3 billion, CEO Demis Hassabis exclusively told Endpoints News. Since its founding in November 2021, Isomorphic has quickly become a leading figure in the fast-growing AI biotech space. The Alphabet subsidiary is applying Google DeepMind’s biology research — particularly its protein-structure predicting model AlphaFold — to drug discovery. Hassabis is CEO of Google DeepMind, where he oversees Alphabet’s AI efforts, as well as CEO of Isomorphic, which now employs about 90 people across its London headquarters and an office in Lausanne, Switzerland. https://lnkd.in/emXua8m6
Alphabet’s AI unit Isomorphic inks drug discovery deals with Eli Lilly, Novartis for up to $3B
https://endpts.com
To view or add a comment, sign in
-
🌟 Exciting News! 🌟 We are thrilled to announce that one of our portfolio companies, CardiaTec Biosciences, has been recognised as one of the "10 Top AI Startups Advancing Drug Discovery in 2023." The world of pharmaceuticals is evolving at a rapid pace, with AI playing a pivotal role in revolutionizing drug discovery and development. From machine learning algorithms identifying potential drug candidates to virtual screening tools that reduce time and costs, the future of drug discovery is undeniably promising. As we approach the close of the fourth quarter, we couldn't be prouder of Cardiatec's achievements and their contribution to the world of medicine. To delve deeper into this recognition and learn more about how AI is transforming the pharma landscape, check out the full article here 🔗 https://lnkd.in/eD4FsP-U #AIinPharma #DrugDiscovery #TopAIStartups2023 #InnovationsInHealthcare
10 Top AI Startups advancing Drug Discovery (2023)
startus-insights.com
To view or add a comment, sign in
-
Persist AI (YC W23), an AI-driven pioneer in drug formulation, has raised $4 million in a seed financing round. Persist AI makes long-lasting injectable medicines more effective. Founded by Christopher Shelner and Karthik Raman, PhD, who previously teamed up at Zymergen where they automated the process of designing biological systems, Persist uses artificial intelligence to quickly test different formulas, check how fast a drug releases, adjust their methods, and prepare for large-scale production. This means they can tackle big issues like how quickly a drug is used up in the body, keeping the formula stable, reducing harmful side effects, and making the drug last longer. What's great is they cut down the time and effort it takes to make these long-lasting medicines. Congrats to the team on the round!
Persist AI Raises $4M in Seed Financing, Rapidly Accelerates Drug Formulation https://lnkd.in/gWaN2zXc
Persist AI Raises $4M in Seed Financing, Rapidly Accelerates Drug Formulation
prnewswire.com
To view or add a comment, sign in
-
Persist AI helps drug companies “formulate” drugs, which essentially means they help design the molecular packaging that will deliver and release the drug to the cells in your body. They use a technology called microspheres. Microspheres can be tuned to evenly release the active agent over a long period of time, making drugs easier to tolerate and mitigating the side effects that come with the large ups and downs in drug concentration when receiving frequent injections. Microsphere technology has been around for decades but turns out to be incredibly hard to produce. Even developing a test formulation can take months, if not years. Here’s the kicker – Persist AI has built an automated process for developing formulations that can tackle this multi-year problem in a matter of weeks! Did I get that right Karthik Raman, PhD? Regardless, great to see the round finally announced and thrilled to have you as part of our W23 portfolio! #venturecapital #biotechnology #pharmaceuticals
Persist AI Raises $4M in Seed Financing, Rapidly Accelerates Drug Formulation https://lnkd.in/gWaN2zXc
Persist AI Raises $4M in Seed Financing, Rapidly Accelerates Drug Formulation
prnewswire.com
To view or add a comment, sign in
-
Weave Bio Launches AutoIND And Secures $10M Seed Funding Learn more & get our take 👇 https://lnkd.in/gWxMA_vg “We’re acutely aware of the high stakes involved in the IND submission process. AutoIND was developed to streamline the tasks best delegated to AI, while leaving regulatory and subject matter experts in the driver seat.” — Ari Caroline, Co-founder and CEO at Weave Bio “As the world rapidly embraces Generative AI, Weave Bio’s platform emerges as a valuable solution for life sciences firms.” — Joel Dudley, Partner at Innovation Endeavors “We believe technology-based innovation is the solution, and it is coming far faster than many realize. Weave’s platform is a strong example of the use of technology to help accelerate delivering new therapies to patients.” — Christine Aylward, Founder and Managing Partner at Magnetic Ventures #bio #funding #SoHCNews
Weave Bio Launches AutoIND and Secures $10M Seed Funding
https://sliceofhealthcare.com
To view or add a comment, sign in
-
AI drug discovery companies are going to fail. Here are 5 reasons why: Headlines boast that AI-made small molecules are entering trials in large numbers. This week's #AACR2024 will show results from several developers with nearly fully digital pipelines, such as Iambic Therapeutics and Insilico Medicine. Despite the hype, a big industry shift to fully AI-powered, lean drug companies is very unlikely. Unless these companies learn from biotech history. Here is what is going to happen: 1️⃣ 𝐍𝐨𝐯𝐞𝐥 𝐝𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐨𝐥𝐝 𝐭𝐚𝐫𝐠𝐞𝐭𝐬: with a focus shifts from science to tech, more IT personnel = less understanding of underlying science = fancy solutions but same old problems. 2️⃣ 𝐋𝐚𝐭𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐠𝐚𝐦𝐞: Pharma companies already started developing their AI solutions. With more access to funding, they'll rather beat biotechs at their own game. 3️⃣ 𝐂𝐚𝐧'𝐭 𝐬𝐭𝐨𝐩 𝐚 𝐫𝐮𝐧𝐧𝐢𝐧𝐠 𝐞𝐥𝐞𝐩𝐡𝐚𝐧𝐭: Pharma is shifting pipelines to large molecules. Will they return to small molecules? 4️⃣ 𝐃𝐢𝐝𝐧'𝐭 𝐬𝐞𝐞 𝐭𝐡𝐞 𝐰𝐚𝐥𝐥 𝐜𝐨𝐦𝐢𝐧𝐠: most of the big failures happen in clinical trials, where costs are higher. Who will finance them without real-world data? 5️⃣ 𝐏𝐨𝐨𝐫 𝐞𝐱𝐢𝐭 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲: AI-driven companies may produce low-value assets. What's the value of something anyone can do? What is then AI good for? 🔹 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞𝐬: not full process, but development sprints 🔹𝐂𝐨𝐬𝐭 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧: leaner structures are good, as long as know-how is retained 🔹𝐋𝐨𝐰𝐞𝐫 𝐞𝐧𝐭𝐫𝐲 𝐛𝐚𝐫𝐫𝐢𝐞𝐫𝐬: with entry barriers reduced to a minimum, the hope is many more biotechs will join the game. This will require new funding models, but has the potential to spur innovation. Do you agree or do you believe AI-driven companies will prevail? Let me know in the comments! ————————— I am Davide - Founder & CEO of Sellomics. With my sales agency I bring innovative solutions from global suppliers to European researchers in #Pharma, #Biotech, and #IVD. Like my content? Click my name + follow + 🔔
To view or add a comment, sign in
-
🚀 Exciting news in the biotech world! 🧬 AION Labs, powerhouse in AI-driven drug discovery, teams up with Amiti Ventures to supercharge Israel's growth as a prime mover in AI-enabled pharmaceutical innovation. Discover how this strategic alliance is poised to revolutionize the journey from lab to life-saving treatments! #AI #DrugDiscovery #BiotechInnovation #StrategicPartnership #HealthcareFuture [Follow the link to learn more about this groundbreaking venture! ➡️ [Your Blog Post Link]]
AION Labs Partners with Amiti to Boost Israel's AI Drug Discoveries
https://funderlyst.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Gene&Cell Therapy >> Bristol Myers eyes major cuts; That $1B AI startup; Pharma reacts to China bill; Q1 earnings highlights; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. It’s been quite a week with some big scoops from the Endpoints team, on top of what is shaping up to be an interesting earnings season. See you next week as we track the biggest themes emerging from media and investor calls. Bristol Myers eyes major cuts About five months into his tenure as Bristol Myers Squibb CEO, Chris Boerner unveiled plans for $1.5 billion in cost-cutting measures, including changes to the pipeline and a workforce reduction of 2,200 by the end of the year. “About 12” programs are getting swept out of the pipeline, and the company is also closing a cell therapy manufacturing site in California, Max Gelman reports. That $1B AI startup A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, launched an ambitious biotech that aims to reinvent drug R&D using artificial intelligence, Andrew Dunn and Ryan Cross report. They chatted with ARCH Venture Partners’ Bob Nelsen about his bet on the startup, Xaira Therapeutics, and interviewed its CEO, former Stanford president Marc Tessier-Lavigne. Pharma reacts to China bill Multiple pharma companies addressed questions about the potential impact of US targeting Chinese companies during their quarterly updates. Novartis said it will change its contract research relationships “over time” to align with new rules, Sanofi is counting on a grandfather clause, while Roche remained unruffled by the bill as it looks to grow roots in the region. On the service provider side, Thermo Fisher said it will be a “long-term beneficiary” as biopharma customers localize their supply chains. AstraZeneca CEO’s pay isn’t just about him Pascal Soriot has been pushing for US-sized CEO pay for more than a decade. The AstraZeneca CEO’s grinding campaign for the big money — set against the backdrop of a massive and durable turnaround — has paid off handsomely. And in winning bigger pay, he is helping to reset the financial scales by which board members use peers’ pay to establish compensation for all the pharma chiefs, John Carroll writes. For his part, Soriot says the pay rise is “really about” his future successor. SPOTLIGHT The next generation of AI biotechs is here. Can they deliver on the hype? Xaira Therapeutics became an instant new leader in the AI biotech field. And this group is hoping they can do what an earlier crop of equally-hyped companies that launched a decade ago couldn’t. Drug and biotech companies on China bill as scrutiny of WuXi continues… #lucidquest #genetherapy #celltherapy
Bristol Myers eyes major cuts; That $1B AI startup; Pharma reacts to China bill; Q1 earnings highlights; and more
https://endpts.com
To view or add a comment, sign in
-
Strategic Medical Adviser / Pharmaceutical Executive / Physician / Business Mentor / Connector and Advocate for Healthcare Access
I was excited to be at Generative AI in Pharma event where industry leaders and startups showcased how Gen AI is transforming biopharma drug development and commercialization. Gen AI is already revolutionizing various areas, such as analysing customer insights, drug pricing, product customization and management of chronic conditions. My key takeaway for founders/startups in AI space: when starting a company or launching a product, clearly define the problem your technology solves. Ensure there is an unmet medical need and that your solution offers a substantial improvement, and this improvement will make a meaningful impact. Key takeaway for pharma: pharmaceutical companies should learn how to collaborate better with tech startups to leverage new technologies to speed up research and development, reduce costs, and get products to market faster. A recent example of such collaboration is Moderna and Sanofi partnership with OpenAI. At the event, six startups presented innovative Gen AI solutions for pharma, including: leveraging data to unlock new biology, predicting binding affinity and molecule toxicity that can speed up identifying the lead compound, running adaptive clinical trials and forecasting clinical trial outcomes. Despite the remaining challenges around ensuring AI-generated answers are reliable and repeatable and patient data is well protected there is lots of excitement about Gen AI driving innovation and efficiency. #GenAI4Pharma #healthdisruptors
To view or add a comment, sign in
-